COMP <GO>
VMD vs ABBV // EV/EBITDA & P/E VALUATION
Viemed Healthcare Inc. (NASDAQ) VS. AbbVie Inc. (NYSE) • 15-METRIC TALLY: VMD 5
— ABBV 8
▲ EV/EBITDA & P/E VALUATION LEADER: VMD
LAST: $9.95 (-0.40%) • MKT CAP: $379.0M
valuation
6.6x
LAST: $290.79 (+1.68%) • MKT CAP: $513.86B
valuation
33.3x
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (VMD VS. ABBV)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | VMD | ABBV | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 57.50% | 70.20% | -12.70 | ABBV | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | 13.00% | 29.00% | -16.00 | ABBV | /roic <GO> |
| EV/EBITDA & P/E Valuation ACTIVE | 6.6x | 33.3x | -26.70 | VMD | /valuation <GO> |
| Free Cash Flow Yield | 3.15% | 3.47% | -0.32 | ABBV | /fcf-yield <GO> |
| Operating Margin | 8.50% | 24.60% | -16.10 | ABBV | /operating-margins <GO> |
| Net Profit Margin | 5.70% | 6.90% | -1.20 | ABBV | /net-margins <GO> |
| Revenue Growth (YoY) | 20.50% | 8.60% | +11.90 | VMD | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 2.27% | -2.27 | ABBV | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 6.59 | 5.33 | +1.26 | VMD | /balance-sheet <GO> |
| Piotroski F-Score Quality | 9/9 | 7/9 | +2.00 | VMD | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 53.1 | 65.1 | -11.99 | ABBV | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 1.15 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | 20.7x | 113.1x | -92.40 | VMD | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $379.0M | $513.86B | -$513.48B | ABBV | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | VMD REV | ABBV REV | VMD GROSS % | ABBV GROSS % | VMD FCF | ABBV FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $270.3M | $61.16B | 57.5% | 70.2% | $11.9M | $17.82B |
| FY 2024 | $224.3M | $56.33B | 59.4% | 70.0% | $1.3M | $17.83B |
| FY 2023 | $183.0M | $54.32B | — | — | $45.2M | $20.39B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
VMD // BETA —
ABBV // BETA 1.15